Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Painless blood test could replace bone marrow biopsy for MPN patients

NCT ID NCT07648433

Diagnosis Sponsor: Weizmann Institute of Science Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 2 times

Summary

This study aims to develop a new blood test that could replace the invasive bone marrow biopsy currently used to diagnose myeloproliferative neoplasms (MPNs), a group of blood cancers. Researchers will collect blood samples from 500 adults with suspected or confirmed MPN and analyze specific blood cells to see if they can accurately detect the disease. If successful, this test could make diagnosis faster, less painful, and more accessible.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test that replaces painful bone marrow biopsies for diagnosing certain blood cancers.
What could go wrong
This is an early observational study, not a treatment trial. The test may not be accurate enough to replace biopsies, and results may take years to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jun 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with MPN, or suspicion for MPN, who are referred to BM will be recruited to the study

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years 2. Confirmed MPN diagnosis, based on the WHO criteria (Barbui 2018), which includes: Polycythemia Vera (PV) Criteria: * Elevated hemoglobin (\>16.5 g/dL for men, \>16.0 g/dL for women), hematocrit (\>49% for men, \>48% for women), or increased red cell mass * Bone marrow biopsy showing hypercellularity with trilineage growth (panmyelosis) * Presence of JAK2 mutation (V617F or exon 12) Essential Thrombocythemia (ET) Criteria: * Platelet count ≥450 ×10⁹/L * Bone marrow biopsy showing proliferation mainly of the megakaryocyte lineage * Not meeting WHO criteria (Alaggio et al., 2022) for other myeloid neoplasms (such as CML, PV, PMF, MDS). * Presence of JAK2, CALR, or MPL mutation Primary Myelofibrosis (PMF) Criteria * Megakaryocytic proliferation and atypia, with or without reticulin fibrosis, and increased marrow cellularity (for prefibrotic/early PMF) or significant reticulin/collagen fibrosis (for overt PMF) * Not meeting criteria for other myeloid neoplasms * Presence of JAK2, CALR, or MPL mutation, or in their absence, another clonal marker 3. Patients who are referred for a bone marrow biopsy due to a suspected diagnosis of MPN Exclusion Criteria: 1. Patients diagnosed with MPN receiving therapy 2. Patients who have undergone a bone marrow transplant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myeloproliferative neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Myeloproliferative Disorders myeloproliferative neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myeloproliferative neoplasm

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.